VIDEO: Study shows ‘curative potential’ in patients with relapsed refractory disease
Jakub Svoboda, MD, of Penn Medicine, discussed data from the ZUMA-12 study presented at the ASH Annual Meeting and Exposition.
The ZUMA-12 trial examined the efficacy of axicabtagene ciloleucel in participants with high-risk large B-cell lymphoma.
“Thinking about using this potent and exciting therapy that can provide curative potential in patients with relapsed refractory disease, but in a population of patients that in theory have curative options in the frontline setting before any chemotherapy, is a provocative, exciting and interesting study,” Svoboda told Healio in a video interview.
Collapse
Neelapu SS, et al. Abstract 405. Presented at: ASH Annual Meeting and Exposition (virtual meeting); Dec. 5-8, 2020.
Read more about